80.48 USD
-0.75 (-0.92%)
At close: Feb 9, 2026
79.98 USD
-0.5 (-0.62%)
Pre-Market: 2/10/2026, 4:00:01 AM
HALO gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. While HALO has a great profitability rating, there are some minor concerns on its financial health. HALO is evaluated to be cheap and growing strongly. This does not happen too often! With these ratings, HALO could be worth investigating further for value and growth investing!.
1. Profitability
1.1 Basic Checks
- HALO had positive earnings in the past year.
- In the past year HALO had a positive cash flow from operations.
- In the past 5 years HALO has always been profitable.
- In the past 5 years HALO always reported a positive cash flow from operatings.
1.2 Ratios
- With an excellent Return On Assets value of 26.81%, HALO belongs to the best of the industry, outperforming 97.71% of the companies in the same industry.
- Looking at the Return On Equity, with a value of 118.17%, HALO belongs to the top of the industry, outperforming 99.62% of the companies in the same industry.
- Looking at the Return On Invested Capital, with a value of 42.77%, HALO belongs to the top of the industry, outperforming 99.24% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for HALO is in line with the industry average of 18.12%.
- The 3 year average ROIC (17.81%) for HALO is below the current ROIC(42.77%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| ROIC | 42.77% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
1.3 Margins
- Looking at the Profit Margin, with a value of 47.91%, HALO belongs to the top of the industry, outperforming 98.28% of the companies in the same industry.
- In the last couple of years the Profit Margin of HALO has declined.
- With an excellent Operating Margin value of 59.33%, HALO belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- HALO's Operating Margin has declined in the last couple of years.
- The Gross Margin of HALO (84.55%) is better than 87.19% of its industry peers.
- In the last couple of years the Gross Margin of HALO has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 59.33% | ||
| PM (TTM) | 47.91% | ||
| GM | 84.55% |
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), HALO is creating value.
- HALO has less shares outstanding than it did 1 year ago.
- Compared to 5 years ago, HALO has less shares outstanding
- HALO has a better debt/assets ratio than last year.
2.2 Solvency
- HALO has an Altman-Z score of 5.54. This indicates that HALO is financially healthy and has little risk of bankruptcy at the moment.
- HALO's Altman-Z score of 5.54 is fine compared to the rest of the industry. HALO outperforms 74.19% of its industry peers.
- HALO has a debt to FCF ratio of 2.51. This is a good value and a sign of high solvency as HALO would need 2.51 years to pay back of all of its debts.
- The Debt to FCF ratio of HALO (2.51) is better than 92.93% of its industry peers.
- HALO has a Debt/Equity ratio of 1.59. This is a high value indicating a heavy dependency on external financing.
- Looking at the Debt to Equity ratio, with a value of 1.59, HALO is doing worse than 76.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | 2.51 | ||
| Altman-Z | 5.54 |
ROIC/WACC3.65
WACC11.71%
2.3 Liquidity
- HALO has a Current Ratio of 1.59. This is a normal value and indicates that HALO is financially healthy and should not expect problems in meeting its short term obligations.
- With a Current ratio value of 1.59, HALO is not doing good in the industry: 79.54% of the companies in the same industry are doing better.
- HALO has a Quick Ratio of 1.37. This is a normal value and indicates that HALO is financially healthy and should not expect problems in meeting its short term obligations.
- HALO has a Quick ratio of 1.37. This is amonst the worse of the industry: HALO underperforms 80.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.37 |
3. Growth
3.1 Past
- HALO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 48.55%, which is quite impressive.
- HALO shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 30.12% yearly.
- Looking at the last year, HALO shows a very strong growth in Revenue. The Revenue has grown by 31.19%.
- The Revenue has been growing by 38.95% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
3.2 Future
- HALO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.78% yearly.
- HALO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.23% yearly.
EPS Next Y58.04%
EPS Next 2Y40.36%
EPS Next 3Y32.57%
EPS Next 5Y17.78%
Revenue Next Year38.12%
Revenue Next 2Y32.39%
Revenue Next 3Y25.48%
Revenue Next 5Y13.23%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 14.29, HALO is valued correctly.
- HALO's Price/Earnings ratio is rather cheap when compared to the industry. HALO is cheaper than 96.56% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 28.06. HALO is valued slightly cheaper when compared to this.
- HALO is valuated reasonably with a Price/Forward Earnings ratio of 9.66.
- HALO's Price/Forward Earnings ratio is rather cheap when compared to the industry. HALO is cheaper than 98.09% of the companies in the same industry.
- HALO's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.86.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.29 | ||
| Fwd PE | 9.66 |
4.2 Price Multiples
- HALO's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. HALO is cheaper than 96.56% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, HALO is valued cheaper than 96.94% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.71 | ||
| EV/EBITDA | 12.2 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The excellent profitability rating of HALO may justify a higher PE ratio.
- HALO's earnings are expected to grow with 32.57% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.25
PEG (5Y)N/A
EPS Next 2Y40.36%
EPS Next 3Y32.57%
5. Dividend
5.1 Amount
- No dividends for HALO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
80.48
-0.75 (-0.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03 2025-11-03/amc
Earnings (Next)02-24 2026-02-24/amc
Inst Owners105.85%
Inst Owner Change-1.53%
Ins Owners0.81%
Ins Owner Change-0.62%
Market Cap9.46B
Revenue(TTM)1.24B
Net Income(TTM)595.49M
Analysts76
Price Target79.56 (-1.14%)
Short Float %11.69%
Short Ratio6.66
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.41%
Min EPS beat(2)3.56%
Max EPS beat(2)19.26%
EPS beat(4)4
Avg EPS beat(4)11.06%
Min EPS beat(4)3.56%
Max EPS beat(4)19.26%
EPS beat(8)7
Avg EPS beat(8)12.2%
EPS beat(12)10
Avg EPS beat(12)9.54%
EPS beat(16)13
Avg EPS beat(16)9.68%
Revenue beat(2)2
Avg Revenue beat(2)6.93%
Min Revenue beat(2)2.18%
Max Revenue beat(2)11.69%
Revenue beat(4)4
Avg Revenue beat(4)7.01%
Min Revenue beat(4)1.36%
Max Revenue beat(4)12.81%
Revenue beat(8)6
Avg Revenue beat(8)5.71%
Revenue beat(12)7
Avg Revenue beat(12)2.94%
Revenue beat(16)9
Avg Revenue beat(16)2.47%
PT rev (1m)2.63%
PT rev (3m)3.08%
EPS NQ rev (1m)14.96%
EPS NQ rev (3m)13.89%
EPS NY rev (1m)4.46%
EPS NY rev (3m)6.45%
Revenue NQ rev (1m)10.99%
Revenue NQ rev (3m)11.2%
Revenue NY rev (1m)3.21%
Revenue NY rev (3m)5.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.29 | ||
| Fwd PE | 9.66 | ||
| P/S | 7.62 | ||
| P/FCF | 15.71 | ||
| P/OCF | 15.49 | ||
| P/B | 18.78 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.2 |
EPS(TTM)5.63
EY7%
EPS(NY)8.33
Fwd EY10.35%
FCF(TTM)5.12
FCFY6.36%
OCF(TTM)5.2
OCFY6.46%
SpS10.57
BVpS4.28
TBVpS-2.22
PEG (NY)0.25
PEG (5Y)N/A
Graham Number23.3
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| ROCE | 53.28% | ||
| ROIC | 42.77% | ||
| ROICexc | 86.79% | ||
| ROICexgc | N/A | ||
| OM | 59.33% | ||
| PM (TTM) | 47.91% | ||
| GM | 84.55% | ||
| FCFM | 48.47% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
ROICexc(3y)23.94%
ROICexc(5y)N/A
ROICexgc(3y)71.73%
ROICexgc(5y)N/A
ROCE(3y)22.19%
ROCE(5y)37.11%
ROICexgc growth 3Y-1.13%
ROICexgc growth 5YN/A
ROICexc growth 3Y-28.16%
ROICexc growth 5YN/A
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
F-Score8
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | 2.51 | ||
| Debt/EBITDA | 0.98 | ||
| Cap/Depr | 10.51% | ||
| Cap/Sales | 0.69% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.59% | ||
| Profit Quality | 101.16% | ||
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.37 | ||
| Altman-Z | 5.54 |
F-Score8
WACC11.71%
ROIC/WACC3.65
Cap/Depr(3y)13.62%
Cap/Depr(5y)33.32%
Cap/Sales(3y)1.21%
Cap/Sales(5y)0.98%
Profit Quality(3y)118.15%
Profit Quality(5y)93.9%
High Growth Momentum
Growth
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
EPS Next Y58.04%
EPS Next 2Y40.36%
EPS Next 3Y32.57%
EPS Next 5Y17.78%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
Revenue Next Year38.12%
Revenue Next 2Y32.39%
Revenue Next 3Y25.48%
Revenue Next 5Y13.23%
EBIT growth 1Y54.59%
EBIT growth 3Y25.97%
EBIT growth 5YN/A
EBIT Next Year61.82%
EBIT Next 3Y38.38%
EBIT Next 5Y15.57%
FCF growth 1Y70.36%
FCF growth 3Y16.28%
FCF growth 5YN/A
OCF growth 1Y65.76%
OCF growth 3Y16.96%
OCF growth 5YN/A
HALOZYME THERAPEUTICS INC / HALO FAQ
Can you provide the ChartMill fundamental rating for HALOZYME THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 7 / 10 to HALO.
Can you provide the valuation status for HALOZYME THERAPEUTICS INC?
ChartMill assigns a valuation rating of 9 / 10 to HALOZYME THERAPEUTICS INC (HALO). This can be considered as Undervalued.
Can you provide the profitability details for HALOZYME THERAPEUTICS INC?
HALOZYME THERAPEUTICS INC (HALO) has a profitability rating of 8 / 10.
What is the financial health of HALOZYME THERAPEUTICS INC (HALO) stock?
The financial health rating of HALOZYME THERAPEUTICS INC (HALO) is 6 / 10.
Can you provide the expected EPS growth for HALO stock?
The Earnings per Share (EPS) of HALOZYME THERAPEUTICS INC (HALO) is expected to grow by 58.04% in the next year.